BLRX — BioLine RX Cashflow Statement
0.000.00%
Last trade - 00:00
- $53.03m
- $36.17m
- $4.80m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -25.4 | -30 | -27.1 | -25 | -60.6 |
Depreciation | |||||
Non-Cash Items | -2.48 | 7.17 | 3.32 | -3.18 | 21.4 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 4.32 | -1.29 | -0.54 | 1.24 | 15.2 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -22.7 | -23.2 | -23.6 | -26.2 | -22.6 |
Capital Expenditures | -0.073 | 0 | -0.097 | -0.316 | -0.297 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 5.33 | 16.7 | -38.1 | 4.32 | 1.74 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 5.26 | 16.7 | -38.2 | 4.01 | 1.44 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 19.2 | 17.9 | 57.7 | 20.4 | 15.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.89 | 11.5 | -3.84 | -2.4 | -6.33 |